UK markets close in 1 hour 10 minutes

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.93+0.04 (+0.51%)
As of 10:20AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.89
Open7.86
Bid7.83 x 1000
Ask7.84 x 1000
Day's range7.81 - 8.03
52-week range2.61 - 24.90
Volume1,032,084
Avg. volume18,329,990
Market cap969.573M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)-0.46
Earnings date04 Aug 2021 - 09 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target est14.50
  • Vaxart (NASDAQ:VXRT) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Vaxart (NASDAQ:VXRT) Is In A Good Position To Deliver On Growth Plans

    There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Vaxart ( NASDAQ:VXRT...

  • Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today
    Motley Fool

    Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

    Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic.

  • Is It Too Late to Buy Vaxart Stock?
    Motley Fool

    Is It Too Late to Buy Vaxart Stock?

    On June 11, Vaxart (NASDAQ: VXRT) stock skyrocketed 22% after Piper Sandler analyst Yasmeen Rahimi initiated coverage of the company with a price target of $18. In setting the price target, the analyst cited the validation of the company's novel adenoviral platform, Ad5, in 200 clinical studies. Vaxart is using the technology to develop a novel, pill-based oral coronavirus vaccine candidate.